The purpose of the note below is to familiarize readers with the current status and future initiatives of cooperation in the field of health technology assessment (HTA) in the European Union (EU). The European Commission is trying to create a framework for efficient collaboration between member states of EU in the field of HTA and is gradually working on strengthening it. The following initiatives, projects and programs have already been implemented: - Project on Coordination and Development of Health Care Technology Assessment in Europe - The European Collaboration for Assessment of Health Interventions and Technology - European Network for Health Technology Assessment - Beneluxa Initiative, The Valletta Declaration, FINOSE and Fair and Affordable Pricing - European Network for Health Technology Assessment Currently there is an ongoing proposal for an HTA Regulation of the European Parliament and the Council, which is the measurable result of this cooperation. A key element of the proposed regulation is a centralized joint clinical assessment (for HTA purposes) of the efficacy of the medicinal product/medical device.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.18388/pb.2019_285 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An integrative analysis reveals cancer risk associated with artificial sweeteners.
J Transl Med
January 2025
Medical College of YiChun University, Xuefu Road No 576, Yichun, 336000, Jiangxi, People's Republic of China.
Background: Artificial sweeteners (AS) have been widely utilized in the food, beverage, and pharmaceutical industries for decades. While numerous publications have suggested a potential link between AS and diseases, particularly cancer, controversy still surrounds this issue. This study aims to investigate the association between AS consumption and cancer risk.
View Article and Find Full Text PDFDevelopment and validation of a five-year cardiovascular risk assessment tool for Asian adults aged 75 years and older.
BMC Geriatr
January 2025
Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, No. 33, Linsen S. Rd., Zhongzheng Dist., Taipei, 100025, Taiwan.
Background: To identify cardiovascular (CV) risk factors in Asian elderly aged 75 years and older and subsequently develop and validate a sex-specific five-year CV risk assessment tool for this population.
Methods: This study included 12,174 patients aged ≥ 75 years without a prior history of cardiovascular disease at a single hospital in Taiwan. Electronic health records were linked to the National Health Insurance Research Database and the National Death Registry to ensure comprehensive health information.
Measuring fluid balance in end-stage renal disease with a wearable bioimpedance sensor.
BMC Nephrol
January 2025
Department of Internal Medicine, Levanger Hospital, Nord-Trøndelag Health Trust, Levanger, Norway.
Background: Accurate assessment of fluid volume and hydration status is essential in many disease states, including patients with chronic kidney disease. The aim of this study was to investigate the ability of a wearable continuous bioimpedance sensor to detect changes in fluid volume in patients undergoing regular hemodialysis (HD).
Methods: 31 patients with end-stage renal disease were enrolled and monitored with a sensor patch (Re:Balans) on the upper back through two consecutive HD sessions and the interdialytic period between.
A practical approach to the spatial-domain calculation of nonprewhitening model observers in computed tomography.
Med Phys
January 2025
Department of Nuclear Medicine and Medical Physics, Karolinska University Hospital, Stockholm, Sweden.
Background: Modern reconstruction algorithms for computed tomography (CT) can exhibit nonlinear properties, including non-stationarity of noise and contrast dependence of both noise and spatial resolution. Model observers have been recommended as a tool for the task-based assessment of image quality (Samei E et al., Med Phys.
View Article and Find Full Text PDFRemotely delivered weight management for people with long COVID and overweight: the randomized wait-list-controlled ReDIRECT trial.
Nat Med
January 2025
General Practice and Primary Care, School of Health and Wellbeing, University of Glasgow, Glasgow, UK.
Long COVID (LC) is a complex multisymptom condition with no known disease-modifying treatments. This wait-list-controlled open-label trial tested whether a remotely delivered structured weight management program could improve respective LC symptoms in people living with overweight. Adults with LC (symptoms >12 weeks) and body mass index >27 kg m (>25 kg m for South Asians) were randomized (n = 234, 1:1) to control (n = 116, usual care) or the remotely delivered structured weight management (n = 118, total diet replacement (850 kcal per day) for 12 weeks, followed by food reintroduction and weight loss maintenance support) via minimization and randomization (80:20) to balance dominant LC symptom, sex, age, ethnicity and postcode-based index of multiple deprivation between groups.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!